Patient characteristics
| . | All patients . |
|---|---|
| Number of patients | 275 |
| Male/female | 174/101 |
| Age at transplant, median (range), y | 7.8 (0.16-19.2) |
| Stem cell source | |
| BM | 116 |
| CB | 155 |
| PBSCs | 4 |
| ATG exposure groups, active ATG × day/mL | 275 |
| AUC <10 | 86 |
| AUC 10-20 | 40 |
| AUC 20-100 | 96 |
| AUC >100 | 53 |
| Conditioned with ATG | 189 |
| Treated with G-CSF | 155 |
| BM | 0 |
| CB | 155 |
| Diagnosis | |
| Malignancy | 144 |
| PID | 53 |
| Benign non-PID | 47 |
| BM failure | 31 |
| Follow-up, days (range) | 1050 (12-3591) |
| . | All patients . |
|---|---|
| Number of patients | 275 |
| Male/female | 174/101 |
| Age at transplant, median (range), y | 7.8 (0.16-19.2) |
| Stem cell source | |
| BM | 116 |
| CB | 155 |
| PBSCs | 4 |
| ATG exposure groups, active ATG × day/mL | 275 |
| AUC <10 | 86 |
| AUC 10-20 | 40 |
| AUC 20-100 | 96 |
| AUC >100 | 53 |
| Conditioned with ATG | 189 |
| Treated with G-CSF | 155 |
| BM | 0 |
| CB | 155 |
| Diagnosis | |
| Malignancy | 144 |
| PID | 53 |
| Benign non-PID | 47 |
| BM failure | 31 |
| Follow-up, days (range) | 1050 (12-3591) |
Values represent number of patients, unless otherwise indicated.
AUC, area under the curve.